Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer
Texas Heart Institute Journal · 2024
DOI: 10.14503/thij-23-8375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Texas Heart Institute Journal, 2024. Verfasst von Allan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, Texas. Hauptthemen laut MEDLINE: Cardiology, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Patients with type 2 diabetes face an elevated risk of cardiovascular disease. This review centers on sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs that, according to a growing body of evidence, may have major potential for managing cardiovascular disease in patients with type 2 diabetes. This review presents findings from multiple clinical trials suggesting that SGLT2 inhibitors can not only serve as preventive therapeutic agents but also play a role in the active management of heart failure. The discussion includes the mechanism of action of SGLT2 inhibitors, emphasizing that they enhance urinary glucose excretion, which could lead to improved glycemic control and contribute to metabolic shifts beneficial to cardiac function. Alongside these cardiometabolic effects, safety concerns and practical considerations for prescribing these agents are addressed, taking into account potential adverse effects such as genitourinary infections and diabetic ketoacidosis as well as the financial implications for patients. Despite these drawbacks, therapeutic indications for SGLT2 inhibitors continue to expand, including for kidney protection, although further research is necessary to fully understand the mechanisms driving the cardioprotective and kidney-protective effects of SGLT2 inhibitors. By synthesizing current knowledge, this review intends to inform and guide clinical decision-making, thereby enhancing cardiovascular disease outcomes in patients with type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Baylor College of Medicine, Houston, Texas.
- Department of Cardiology, The Texas Heart Institute, Houston, Texas.
- Aga Khan University, Karachi, Pakistan.
- Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas.
Zitieren
APA
Zhang, A., Kalil, R., Marzec, A., Coulter, S. A., Virani, S., Patel, K. V., & Segar, M. W. (2024). Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer. Texas Heart Institute Journal. https://doi.org/10.14503/thij-23-8375
Vancouver
Zhang A, Kalil R, Marzec A, Coulter SA, Virani S, Patel KV, et al. Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer. Texas Heart Institute Journal. 2024. doi:10.14503/thij-23-8375
BibTeX
@article{Zhang2024,
author = {Zhang, Allan and Kalil, Ramsey and Marzec, Alexander and Coulter, Stephanie A and Virani, Salim and Patel, Kershaw V and Segar, Matthew W},
title = {Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer},
journal = {Texas Heart Institute Journal},
year = {2024},
doi = {10.14503/thij-23-8375}
}
EUVIMED